ES2684758T3 - Procedimiento para diagnosticar fibrosis hepática - Google Patents

Procedimiento para diagnosticar fibrosis hepática Download PDF

Info

Publication number
ES2684758T3
ES2684758T3 ES15720014.8T ES15720014T ES2684758T3 ES 2684758 T3 ES2684758 T3 ES 2684758T3 ES 15720014 T ES15720014 T ES 15720014T ES 2684758 T3 ES2684758 T3 ES 2684758T3
Authority
ES
Spain
Prior art keywords
liver fibrosis
procedure
diagnose liver
rdna
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15720014.8T
Other languages
English (en)
Inventor
Michael Courtney
Benjamin LELOUVIER
Massimo Federici
José Manuel Fernández-Real
Sandrine PAÏSSÉ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut dInvestigacio Biomedica de Girona Dr Josep Trueta Idibgi
Vaiomer
Degli Studi Di Roma Tor Vergata, University of
Universita degli Studi di Roma Tor Vergata
Original Assignee
Fundacio Institut dInvestigacio Biomedica de Girona Dr Josep Trueta Idibgi
Vaiomer
Degli Studi Di Roma Tor Vergata, University of
Universita degli Studi di Roma Tor Vergata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut dInvestigacio Biomedica de Girona Dr Josep Trueta Idibgi, Vaiomer, Degli Studi Di Roma Tor Vergata, University of, Universita degli Studi di Roma Tor Vergata filed Critical Fundacio Institut dInvestigacio Biomedica de Girona Dr Josep Trueta Idibgi
Application granted granted Critical
Publication of ES2684758T3 publication Critical patent/ES2684758T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un procedimiento in vitro para diagnosticar la fibrosis hepática en un sujeto que padece obesidad, y dicho procedimiento comprende los pasos de: a1) medir la concentración de ADNr 16S bacteriano, o la relación de la cantidad de ADNr 16S bacteriano con la cantidad de ADN total, en una muestra biológica del sujeto seleccionado del grupo que consiste en sangre, suero y muestra de plasma; y b) según el resultado de la medición en el paso a1), diagnosticar fibrosis hepática en el sujeto que padece obesidad.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11

Claims (1)

  1. imagen1
    imagen2
ES15720014.8T 2014-04-23 2015-04-23 Procedimiento para diagnosticar fibrosis hepática Active ES2684758T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305597 2014-04-23
EP14305597 2014-04-23
PCT/EP2015/058772 WO2015162200A1 (en) 2014-04-23 2015-04-23 Method for diagnosing hepatic fibrosis

Publications (1)

Publication Number Publication Date
ES2684758T3 true ES2684758T3 (es) 2018-10-04

Family

ID=50679975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15720014.8T Active ES2684758T3 (es) 2014-04-23 2015-04-23 Procedimiento para diagnosticar fibrosis hepática

Country Status (5)

Country Link
US (1) US10337069B2 (es)
EP (1) EP3134543B1 (es)
CN (1) CN106661617A (es)
ES (1) ES2684758T3 (es)
WO (1) WO2015162200A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190062810A1 (en) * 2015-10-09 2019-02-28 Vaiomer Method for diagnosing hepatic fibrosis based on bacterial profile and diversity
US20200132670A1 (en) * 2018-10-18 2020-04-30 Korea Research Institute Of Chemical Technology Fatty liver and liver fibrosis evaluation system based on impedance
CN110229877A (zh) * 2019-06-21 2019-09-13 广东药科大学附属第一医院 一种miRNA在制备预防或诊断血脂异常肝郁证试剂中的应用
RU2759672C2 (ru) * 2019-12-12 2021-11-16 Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) Способ дифференциации причин развития фиброза печени начального уровня при хронических вирусных гепатитах В и С
CN112819786B (zh) * 2021-02-01 2023-11-28 北京精康科技有限责任公司 基于多个肝静脉波形图的肝脏血液动力检测装置
CN112819785B (zh) * 2021-02-01 2024-06-07 北京精康科技有限责任公司 一种肝脏血液动力检测装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2021511A4 (en) * 2006-05-03 2010-02-10 Geisinger Clinic METHODS OF DIAGNOSIS AND PREDICTION OF NON ALCOHOLIC STHEATHYPATITIS (NASH)
EP2396425A2 (en) * 2009-02-13 2011-12-21 Institut National De La Sante Et De La Recherche Medicale Bacterial dna as markers of cardiovascular and/or metabolic disease
WO2012131087A1 (en) * 2011-03-31 2012-10-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for predicting insulinopenic type 2 diabetes
EP2691537A1 (en) 2011-03-31 2014-02-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Method for predicting abdominal obesity

Also Published As

Publication number Publication date
EP3134543B1 (en) 2018-04-11
EP3134543A1 (en) 2017-03-01
US20170044612A1 (en) 2017-02-16
WO2015162200A1 (en) 2015-10-29
US10337069B2 (en) 2019-07-02
CN106661617A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
ES2684758T3 (es) Procedimiento para diagnosticar fibrosis hepática
ES2506116T3 (es) Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
MX2015012437A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
CL2017001940A1 (es) Dispositivo de medición de la calidad del suelo
MX2013001042A (es) Biomarcadores de cancer pancreatico y usos de los mismos.
MX386528B (es) Metodos para la cuantificacion de los niveles de insulina por espectrometria de masas.
MX337196B (es) Metodo para analizar especimenes biologicos por medio de imagenes espectrales.
MX2019015016A (es) Ensayos para la deteccion de una sola molecula y uso de los mismos.
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
MX355416B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
CL2017002101A1 (es) Dispositivo, plataforma y ensayo para evaluación de células
BRPI0811536B8 (pt) método para detectar uma cetona biologicamente ativa e método para extração
ES2564138T3 (es) Ensayo para Hemaglutinina del virus de la influenza
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
BR112019006862A2 (pt) dispositivo de análise e método para testagem de uma amostra
EP2937421A3 (en) Biomarker for predicting effect of an anti-C-met antibody
WO2013167727A3 (en) Method for determining arthritis relapse risk
ES2578160T3 (es) Procedimiento de diagnóstico de infecciones de sitio quirúrgico
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal
AR071931A1 (es) Metodo analitico para monitorear la potencia y estabilidad de una vacuna
ES2523903B1 (es) Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática
WO2015193552A3 (en) Means and methods for determining risk of type-1 diabetes by serum protein biomarkers